243 related articles for article (PubMed ID: 33624162)
1. Synthesis and Anticancer Properties of Functionalized 1,6-Naphthyridines.
Lavanya M; Lin C; Mao J; Thirumalai D; Aabaka SR; Yang X; Mao J; Huang Z; Zhao J
Top Curr Chem (Cham); 2021 Feb; 379(2):13. PubMed ID: 33624162
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of indeno[1,5]naphthyridines as topoisomerase I (TopI) inhibitors with antiproliferative activity.
Alonso C; Fuertes M; González M; Rubiales G; Tesauro C; Knudsen BR; Palacios F
Eur J Med Chem; 2016 Jun; 115():179-90. PubMed ID: 27017547
[TBL] [Abstract][Full Text] [Related]
3. Straightforward synthesis and biological evaluation as topoisomerase I inhibitors and antiproliferative agents of hybrid Chromeno[4,3-b][1,5]Naphthyridines and Chromeno[4,3-b][1,5]Naphthyridin-6-ones.
Martín-Encinas E; Rubiales G; Knudssen BR; Palacios F; Alonso C
Eur J Med Chem; 2019 Sep; 178():752-766. PubMed ID: 31229877
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 1,5-naphthyridines as topoisomerase I inhibitors. A new family of antiproliferative agents.
Alonso C; Fuertes M; González M; Rodríguez-Gascón A; Rubiales G; Palacios F
Curr Top Med Chem; 2014; 14(23):2722-8. PubMed ID: 25515747
[TBL] [Abstract][Full Text] [Related]
5. Fused chromeno and quinolino[1,8]naphthyridines: Synthesis and biological evaluation as topoisomerase I inhibitors and antiproliferative agents.
Martín-Encinas E; Rubiales G; Knudsen BR; Palacios F; Alonso C
Bioorg Med Chem; 2021 Jun; 40():116177. PubMed ID: 33962152
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative activity of novel benzo[b][1,6]naphthyridines in human solid tumor cell lines.
Rudys S; Ríos-Luci C; Pérez-Roth E; Cikotiene I; Padrón JM
Bioorg Med Chem Lett; 2010 Mar; 20(5):1504-6. PubMed ID: 20144871
[TBL] [Abstract][Full Text] [Related]
7. Microwave-assisted synthesis of pyrimido[4,5-b][1,6]naphthyridin-4(3H)-ones with potential antitumor activity.
Insuasty B; Becerra D; Quiroga J; Abonia R; Nogueras M; Cobo J
Eur J Med Chem; 2013 Feb; 60():1-9. PubMed ID: 23279862
[TBL] [Abstract][Full Text] [Related]
8. 1,8-Naphthyridine Derivatives: A Review of Multiple Biological Activities.
Madaan A; Verma R; Kumar V; Singh AT; Jain SK; Jaggi M
Arch Pharm (Weinheim); 2015 Dec; 348(12):837-60. PubMed ID: 26548568
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of new 2-arylnaphthyridin-4-ones as potent antitumor agents targeting tumorigenic cell lines.
Liu CY; Cheng YY; Chang LC; Huang LJ; Chou LC; Huang CH; Tsai MT; Liao CC; Hsu MH; Lin HY; Wu TS; Wen YF; Zhao Y; Kuo SC; Lee KH
Eur J Med Chem; 2015 Jan; 90():775-87. PubMed ID: 25528332
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anticancer activity of novel dihydrobenzofuro[4,5-b][1,8]naphthyridin-6-one derivatives.
Kang JA; Yang Z; Lee JY; De U; Kim TH; Park JY; Lee HJ; Park YJ; Chun P; Kim HS; Jeong LS; Moon HR
Bioorg Med Chem Lett; 2011 Oct; 21(19):5730-4. PubMed ID: 21885273
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and cytostatic properties of some 6H-Indolo[2, 3-b][1, 8]naphthyridine derivatives.
Mastalarz H; Jasztold-Howorko R; Rulko F; Croisy A; Carrez D
Arch Pharm (Weinheim); 2004 Aug; 337(8):434-9. PubMed ID: 15293262
[TBL] [Abstract][Full Text] [Related]
12. Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
Arepalli SK; Lee C; Sim S; Lee K; Jo H; Jun KY; Kwon Y; Kang JS; Jung JK; Lee H
Bioorg Med Chem; 2018 Oct; 26(18):5181-5193. PubMed ID: 30253887
[TBL] [Abstract][Full Text] [Related]
13. Benzo[c][2,7]naphthyridines as inhibitors of PDK-1.
Kim KH; Wissner A; Floyd MB; Fraser HL; Wang YD; Dushin RG; Hu Y; Olland A; Guo B; Arndt K
Bioorg Med Chem Lett; 2009 Sep; 19(17):5225-8. PubMed ID: 19628388
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
Deady LW; Rodemann T; Zhuang L; Baguley BC; Denny WA
J Med Chem; 2003 Mar; 46(6):1049-54. PubMed ID: 12620081
[TBL] [Abstract][Full Text] [Related]
15. Anticancer and immunomodulatory activities of novel 1,8-naphthyridine derivatives.
Kumar V; Madaan A; Sanna VK; Vishnoi M; Joshi N; Singh AT; Jaggi M; Sharma PK; Irchhaiya R; Burman AC
J Enzyme Inhib Med Chem; 2009 Oct; 24(5):1169-78. PubMed ID: 19555167
[TBL] [Abstract][Full Text] [Related]
16. Antineoplastic agents. 499. Synthesis of hystatin 2 and related 1H-benzo[de][1,6]-naphthyridinium salts from aaptamine.
Pettit GR; Hoffmann H; Herald DL; Blumberg PM; Hamel E; Schmidt JM; Chang Y; Pettit RK; Lewin NE; Pearce LV
J Med Chem; 2004 Mar; 47(7):1775-82. PubMed ID: 15027869
[TBL] [Abstract][Full Text] [Related]
17. Antineoplastic agents 491. Synthetic conversion of aaptamine to isoaaptamine, 9-demethylaaptamine, and 4-methylaaptamine.
Pettit GR; Hoffmann H; Herald DL; McNulty J; Murphy A; Higgs KC; Hamel E; Lewin NE; Pearce LV; Blumberg PM; Pettit RK; Knight JC
J Org Chem; 2004 Apr; 69(7):2251-6. PubMed ID: 15049616
[TBL] [Abstract][Full Text] [Related]
18. 1,8-Naphthyridine-3-carboxamide derivatives with anticancer and anti-inflammatory activity.
Kumar V; Jaggi M; Singh AT; Madaan A; Sanna V; Singh P; Sharma PK; Irchhaiya R; Burman AC
Eur J Med Chem; 2009 Aug; 44(8):3356-62. PubMed ID: 19361894
[TBL] [Abstract][Full Text] [Related]
19. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.
Bilodeau MT; Balitza AE; Hoffman JM; Manley PJ; Barnett SF; Defeo-Jones D; Haskell K; Jones RE; Leander K; Robinson RG; Smith AM; Huber HE; Hartman GD
Bioorg Med Chem Lett; 2008 Jun; 18(11):3178-82. PubMed ID: 18479914
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents.
Feng W; Satyanarayana M; Cheng L; Liu A; Tsai YC; Liu LF; LaVoie EJ
Bioorg Med Chem; 2008 Oct; 16(20):9295-301. PubMed ID: 18829334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
